Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03057795 · ClinicalTrials.gov registry record · Phase 2

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

A Phase 2 study of Refractory Hodgkin Lymphoma and Classic Hodgkin Lymphoma, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
62
Enrollment target
6
Study locations

NCT03057795 is a Phase 2 study of Refractory Hodgkin Lymphoma and Classic Hodgkin Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 62 participants, above the 37-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (68% higher). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03057795, a Phase 2 study of Refractory Hodgkin Lymphoma and Classic Hodgkin Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
62 participants
Enrollment target
6
Study locations

Study Summary

This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and brentuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Refractory Hodgkin Lymphoma Classic Hodgkin Lymphoma Recurrent Hodgkin Lymphoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Nivolumab
  • DRUG Brentuximab Vedotin

Study Locations (6)

California

  • City of Hope Medical Center - Duarte

Minnesota

  • Mayo Clinic in Rochester - Rochester

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • M D Anderson Cancer Center - Houston

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2017-04-03
Est. Completion 2026-03-25
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03057795

The ClinicalTrials.gov registry entry for NCT03057795 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 37-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (68% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Refractory Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT03057795 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Minnesota, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03057795 about?

NCT03057795 is a clinical study titled "Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma". This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolu...

What is the current status of trial NCT03057795?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2017-04-03. Estimated completion is 2026-03-25.

What conditions does trial NCT03057795 study?

This clinical trial studies the following conditions: Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma.

What interventions are being tested in trial NCT03057795?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG).

Who is sponsoring clinical trial NCT03057795?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03057795 being conducted?

This trial has 6 study locations across California, Minnesota, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Hodgkin Lymphoma

All registered trials for this condition

Classic Hodgkin Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.